Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nls Pharmaceutics Ltd WT (NQ: NLSPW )

0.0297 -0.0013 (-4.19%)
Streaming Delayed Price Updated: 12:57 PM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,759
Open 0.0495
Bid (Size) 0.0250 (8)
Ask (Size) 0.0500 (8)
Prev. Close 0.0310
Today's Range 0.0297 - 0.0572
52wk Range 0.0111 - 0.1700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NLS Pharmaceutics Announces Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Via ACCESSWIRE

Performance

YTD
-57.57%
-57.57%
1 Month
+12.50%
+12.50%
3 Month
+15.56%
+15.56%
6 Month
-46.77%
-46.77%
1 Year
-79.23%
-79.23%

More News

Read More
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
Via ACCESSWIRE
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Via ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Via ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Via ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
Via ACCESSWIRE
Notice of Deficiency with Nasdaq Continued Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
Via ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
Via ACCESSWIRE
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Via ACCESSWIRE
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
Via ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Via ACCESSWIRE
NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
Via Benzinga
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.